Vedtofte, L., Bahne, E., Foghsgaard, S., Bagger, J. I., Andreasen, C., Strandberg, C., . . . Vilsbøll, T. (2020). One Year’s Treatment with the Glucagon-Like Peptide 1 Receptor Agonist Liraglutide Decreases Hepatic Fat Content in Women with Nonalcoholic Fatty Liver Disease and Prior Gestational Diabetes Mellitus in a Randomized, Placebo-Controlled Trial. J Clin Med.
Styl ChicagoVedtofte, Louise, et al. "One Year’s Treatment With the Glucagon-Like Peptide 1 Receptor Agonist Liraglutide Decreases Hepatic Fat Content in Women With Nonalcoholic Fatty Liver Disease and Prior Gestational Diabetes Mellitus in a Randomized, Placebo-Controlled Trial." J Clin Med 2020.
Citace podle MLAVedtofte, Louise, et al. "One Year’s Treatment With the Glucagon-Like Peptide 1 Receptor Agonist Liraglutide Decreases Hepatic Fat Content in Women With Nonalcoholic Fatty Liver Disease and Prior Gestational Diabetes Mellitus in a Randomized, Placebo-Controlled Trial." J Clin Med 2020.